BioCentury | Jul 6, 2018
Company News

Management tracks: Goldman Sachs, Acceleron

...of R&D at pain company Tremeau Pharmaceuticals Inc. (Cambridge, Mass.). Small molecule drug discovery company C4X Discovery Holdings plc...
BioCentury | Mar 30, 2018
Company News

Indivior licenses preclinical addiction candidate from C4X Discovery

...buprenorphine (RBP-6000) in the U.S. this month. Both drugs are for treating opioid use disorder. C4X Discovery...
...family for multiple indications. C4X Discovery Holdings plc (LSE:C4XD), Manchester, U.K. Indivior plc (LSE:INDV), Richmond, Va. Business: Neurology Mary Romeo buprenorphine/naloxone RBP-6000 Sublocade Suboxone C4X Discovery Holdings plc Indivior...
BioCentury | Mar 29, 2018
Company News

C4X gains after addiction deal with Indivior

...buprenorphine (RBP-6000) in the U.S. this month. Both drugs are for treating opioid use disorder. C4X Discovery...
...compounds in the patent family for multiple indications. Indivior add 4.6p to 407.6p on Thursday. Mary Romeo buprenorphine/naloxone C4X_3256 RBP-6000 Sublocade Suboxone C4X Discovery Holdings plc Indivior...
BioCentury | Jan 4, 2018
Translation in Brief

Designing specificity

...Solving a key problem in the orexin field, C4X Discovery Holdings plc (LSE:C4XD) has described how its technology platform...
...of the parts of their molecules that were OX2R-specific.” Clive Dix, C4X Discovery Holdings In November, C4X Discovery...
...and described how its NMR-based platform produced a compound that could distinguish the two subtypes. C4X Discovery...
BioCentury | Oct 3, 2016
Company News

Evotec, C4X Discovery deal

...at any time. The partners declined to disclose further details. Evotec AG (Xetra:EVT), Hamburg, Germany C4X Discovery Holdings plc...
BioCentury | Sep 27, 2016
Company News

Management tracks

...Respiratory company Verona Pharma plc (LSE:VRP; Xetra:I9S) named Piers Morgan CFO. He was CEO at C4X Discovery Holdings plc...
BioCentury | Sep 12, 2016
Financial News

C4X Discovery proposes placing

C4X Discovery Holdings plc (LSE:C4XD), Manchester, U.K. Business: Computational chemistry/biology, Neurology, Endocrine/Metabolic Date announced: 2016-09-06 Type: Placing To be raised: Up to L5 million ($6.7 million) Shares: 4.9 million Price: 102p Shares outstanding prior: 32.5...
BioCentury | May 10, 2016
Company News

Management tracks

...Arsanis Inc. (Waltham, Mass.) promoted Rene Russo to president and CEO from chief development officer. C4X Discovery Holdings plc...
BioCentury | Mar 7, 2016
Company News

Adorial, C4X Discovery deal

...analysis technology will augment C4X’s small molecule discovery platform. Adorial Ltd. , High Wycombe, U.K. C4X Discovery Holdings plc...
BioCentury | Dec 2, 2015
Company News

Management tracks

...officer, effective Jan. 4. He was SVP and associate general counsel at Pfizer Inc. (NYSE:PFE). C4X Discovery...
Items per page:
1 - 10 of 24
BioCentury | Jul 6, 2018
Company News

Management tracks: Goldman Sachs, Acceleron

...of R&D at pain company Tremeau Pharmaceuticals Inc. (Cambridge, Mass.). Small molecule drug discovery company C4X Discovery Holdings plc...
BioCentury | Mar 30, 2018
Company News

Indivior licenses preclinical addiction candidate from C4X Discovery

...buprenorphine (RBP-6000) in the U.S. this month. Both drugs are for treating opioid use disorder. C4X Discovery...
...family for multiple indications. C4X Discovery Holdings plc (LSE:C4XD), Manchester, U.K. Indivior plc (LSE:INDV), Richmond, Va. Business: Neurology Mary Romeo buprenorphine/naloxone RBP-6000 Sublocade Suboxone C4X Discovery Holdings plc Indivior...
BioCentury | Mar 29, 2018
Company News

C4X gains after addiction deal with Indivior

...buprenorphine (RBP-6000) in the U.S. this month. Both drugs are for treating opioid use disorder. C4X Discovery...
...compounds in the patent family for multiple indications. Indivior add 4.6p to 407.6p on Thursday. Mary Romeo buprenorphine/naloxone C4X_3256 RBP-6000 Sublocade Suboxone C4X Discovery Holdings plc Indivior...
BioCentury | Jan 4, 2018
Translation in Brief

Designing specificity

...Solving a key problem in the orexin field, C4X Discovery Holdings plc (LSE:C4XD) has described how its technology platform...
...of the parts of their molecules that were OX2R-specific.” Clive Dix, C4X Discovery Holdings In November, C4X Discovery...
...and described how its NMR-based platform produced a compound that could distinguish the two subtypes. C4X Discovery...
BioCentury | Oct 3, 2016
Company News

Evotec, C4X Discovery deal

...at any time. The partners declined to disclose further details. Evotec AG (Xetra:EVT), Hamburg, Germany C4X Discovery Holdings plc...
BioCentury | Sep 27, 2016
Company News

Management tracks

...Respiratory company Verona Pharma plc (LSE:VRP; Xetra:I9S) named Piers Morgan CFO. He was CEO at C4X Discovery Holdings plc...
BioCentury | Sep 12, 2016
Financial News

C4X Discovery proposes placing

C4X Discovery Holdings plc (LSE:C4XD), Manchester, U.K. Business: Computational chemistry/biology, Neurology, Endocrine/Metabolic Date announced: 2016-09-06 Type: Placing To be raised: Up to L5 million ($6.7 million) Shares: 4.9 million Price: 102p Shares outstanding prior: 32.5...
BioCentury | May 10, 2016
Company News

Management tracks

...Arsanis Inc. (Waltham, Mass.) promoted Rene Russo to president and CEO from chief development officer. C4X Discovery Holdings plc...
BioCentury | Mar 7, 2016
Company News

Adorial, C4X Discovery deal

...analysis technology will augment C4X’s small molecule discovery platform. Adorial Ltd. , High Wycombe, U.K. C4X Discovery Holdings plc...
BioCentury | Dec 2, 2015
Company News

Management tracks

...officer, effective Jan. 4. He was SVP and associate general counsel at Pfizer Inc. (NYSE:PFE). C4X Discovery...
Items per page:
1 - 10 of 24